PLoS ONE (Jan 2020)

Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.

  • Fabian Schnitzler,
  • Matthias Friedrich,
  • Marianne Angelberger,
  • Julia Diegelmann,
  • Johannes Stallhofer,
  • Christiane Wolf,
  • Joel Dütschler,
  • Samuel Truniger,
  • Torsten Olszak,
  • Florian Beigel,
  • Cornelia Tillack,
  • Peter Lohse,
  • Stephan Brand

DOI
https://doi.org/10.1371/journal.pone.0236421
Journal volume & issue
Vol. 15, no. 7
p. e0236421

Abstract

Read online

BackgroundNOD2 variants are the strongest genetic predictors for susceptibility to Crohn's disease (CD). However, the clinical value of NOD2 on an individual patient level remains controversial. We aimed to define the predictive power of the major NOD2 mutations regarding complicated CD in a large single center cohort.Methods1076 CD patients were prospectively genotyped for the three common CD-associated NOD2 mutations rs2066844, rs2066845, and rs2066847, followed by detailed genotype-phenotype analyses.ResultsOverall, 434 CD patients (40.3%) carried at least one of the three main NOD2 mutations. A significantly higher minor allele frequency (15.6%) of the NOD2 frameshift mutation p.Leu1007fsX1008 (rs2066847) was seen in patients with aggressive disease compared to 8.2% in patients with mild disease (p = 2.6 x 10-5). Moreover, a total of 54 CD patients (5.0%) were homozygous for this NOD2 frameshift mutation. 100% of these patients had ileal disease compared to 82% of NOD2 wild-type carriers (pConclusionHomozygosity for Leu1007fsX1008 is an excellent biomarker for predicting complicated CD on an individual patient level. Active smoking and homozygosity for this mutation is associated with a 100% risk for developing ileal stenosis requiring CD-related surgery. In these patients, smoking cessation and early initiation of immunosuppressive strategies may be beneficial.